BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31110157)

  • 1. Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.
    Dahl ES; Buj R; Leon KE; Newell JM; Imamura Y; Bitler BG; Snyder NW; Aird KM
    Mol Cancer Res; 2019 Aug; 17(8):1710-1720. PubMed ID: 31110157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
    Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
    J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
    Hooda J; Novak M; Salomon MP; Matsuba C; Ramos RI; MacDuffie E; Song M; Hirsch MS; Lester J; Parkash V; Karlan BY; Oren M; Hoon DS; Drapkin R
    Cancer Res; 2019 Feb; 79(4):760-772. PubMed ID: 30563893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.
    Gambaro K; Quinn MC; Cáceres-Gorriti KY; Shapiro RS; Provencher D; Rahimi K; Mes-Masson AM; Tonin PN
    BMC Cancer; 2015 Mar; 15():135. PubMed ID: 25886299
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Hillman JC; Pugacheva EM; Barger CJ; Sribenja S; Rosario S; Albahrani M; Truskinovsky AM; Stablewski A; Liu S; Loukinov DI; Zentner GE; Lobanenkov VV; Karpf AR; Higgins MJ
    Mol Cancer Res; 2019 Oct; 17(10):2051-2062. PubMed ID: 31292201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long Non-Coding RNA HAND2-AS1 Acts as a Tumor Suppressor in High-Grade Serous Ovarian Carcinoma.
    Gokulnath P; de Cristofaro T; Manipur I; Di Palma T; Soriano AA; Guarracino MR; Zannini M
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion.
    Ojasalu K; Brehm C; Hartung K; Nischak M; Finkernagel F; Rexin P; Nist A; Pavlakis E; Stiewe T; Jansen JM; Wagner U; Gattenlöhner S; Bräuninger A; Müller-Brüsselbach S; Reinartz S; Müller R
    Mol Oncol; 2020 Sep; 14(9):2142-2162. PubMed ID: 32533757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.
    Klinkebiel D; Zhang W; Akers SN; Odunsi K; Karpf AR
    Mol Cancer Res; 2016 Sep; 14(9):787-94. PubMed ID: 27259716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
    Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
    J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
    Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE
    Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
    Ghannam-Shahbari D; Jacob E; Kakun RR; Wasserman T; Korsensky L; Sternfeld O; Kagan J; Bublik DR; Aviel-Ronen S; Levanon K; Sabo E; Larisch S; Oren M; Hershkovitz D; Perets R
    Oncogene; 2018 Apr; 37(17):2213-2224. PubMed ID: 29379162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR.
    Bapat J; Yamamoto TM; Woodruff ER; Qamar L; Mikeska RG; Aird KM; Watson ZL; Brubaker LW; Bitler BG
    Cancer Gene Ther; 2024 Feb; 31(2):300-310. PubMed ID: 38030811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
    Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
    Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic activation of POTE genes in ovarian cancer.
    Sharma A; Albahrani M; Zhang W; Kufel CN; James SR; Odunsi K; Klinkebiel D; Karpf AR
    Epigenetics; 2019 Feb; 14(2):185-197. PubMed ID: 30764732
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
    Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.
    Nam EJ; Kim S; Lee TS; Kim HJ; Lee JY; Kim SW; Kim JH; Kim YT
    Oncotarget; 2016 Oct; 7(43):70524-70534. PubMed ID: 27655640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.